A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect of PTI-428 in Subjects With Cystic Fibrosis
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2018
At a glance
- Drugs PTI 428 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Proteostasis Therapeutics
- 01 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Aug 2018.
- 06 Jul 2018 Status changed from planning to recruiting.
- 17 Apr 2018 According to a Proteostasis Therapeutics media release, this study intended to expand population of CF subjects in a Phase III study (see profile 700295090). Dr. Jennifer Taylor-Cousar is a a lead investigator.